Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study
Authors' conclusion
PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision-making in obesity care.
Study context
- Population
- People with obesity and health care providers in the United States, surveyed in 2022
- Participants
- 1,007 vs 474
- Exposure
- People with obesity (PwO) vs health care providers (HCPs)
- PwOn = 1,007
- HCPsn = 474
- Outcome
- Perceptions of and drivers/barriers to antiobesity medication (AOM) use
Methodological detailssurvey, descriptive statistics
- Survey
- Descriptive statistics
Main finding
As reported in the abstract
- Both groups emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity
- PwO reported willingness to take newly approved antiobesity medication (AOMs) long term
- HCPs believed patients would adhere to AOMs long term if they experienced success
- Both perceived increased effectiveness of combining AOMs with HCP-guided lifestyle intervention
- Barriers to long-term AOM use: concerns about long-term side effects and outcomes, costs and insurance coverage, and perception of AOMs not aligned with chronic disease treatment
Observational data: associations, not effects.
Original publication
Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study. Obesity (Silver Spring). Published 24 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →